GlassScriptPhysician profile
Cristal Sumerlin
NPI 1932796869
$2,796.45
in general payments reported to CMS, 2019-2025
27 companies · $903 in 2025
The $903 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $196 · 2022: $334 · 2023: $729 · 2024: $634 · 2025: $903.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,266.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $448.21 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $438.63 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $284.70 | 2021-2025 | Evenity, Repatha, Otezla |
| Kowa Pharmaceuticals America, INC. | $221.47 | 2021-2025 | Zoryve, Livalo, Seglentis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $195.70 | 2021-2025 | Jardiance, Tradjenta |
| Verona Pharma, INC. | $168.45 | 2025 | Ohtuvayre |
| Lilly USA, LLC | $166.82 | 2022-2024 | Mounjaro, Emgality, Jardiance |
| Glaxosmithkline, LLC. | $156.39 | 2023-2024 | Arexvy, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $97.61 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $81.11 | 2023-2024 | Rexulti |
| Amarin Pharma, INC. | $59.38 | 2021-2023 | |
| Exact Sciences Corporation | $59.14 | 2023-2025 | Cologuard Collection Kit |
| Intra-Sana Laboratories | $50.00 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Dexcom, INC. | $41.60 | 2025 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $41.00 | 2022-2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $37.54 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $36.28 | 2023-2024 | |
| Mannkind Corporation | $28.95 | 2022-2023 | Afrezza |
| Lundbeck LLC | $25.66 | 2024 | Rexulti |
| Pfizer INC. | $24.76 | 2023 | |
| Eisai INC. | $21.76 | 2025 | |
| Grifols USA, LLC | $20.21 | 2024 | Prolastin-C Liquid |
| Si-Bone, INC. | $20.15 | 2022 | |
| Esperion Therapeutics, INC. | $19.17 | 2021 | |
| Hologic Sales and Service, LLC | $18.65 | 2024 | Aptima |
| Collegium Pharmaceutical, INC. | $16.86 | 2025 | Belbuca |
| Sumitomo Pharma America, INC. | $16.25 | 2025 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cristal Sumerlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.